Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US4792447A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 27, 1983 |
| Grant date | Dec 20, 1988 |
| Priority date | — |
| Expiry date | May 27, 2003 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Highly specific antibodies directed against immunoglobulin determinants coupled to one or more toxin molecules provide antibody-toxin conjugates which are useful in selectively inhibiting the growth of target immunoglobulin generating cells. The antibody-toxin conjugate consists of an antibody specific for a selected immunoglobulin determinant including isotypic, allotypic or idiotypic variable determinants, coupled to one or more toxin molecules. Anti-idiotype toxin conjugates are provided which have specificity which distinguishes B cell tumor cells from normal B cells. Also disclosed is an antibody-toxin conjugate consisting of anti-IgD A chain. The antibody-toxin conjugate is used as a cell or tumor specific cytotoxic agent directed selectively against those cells expressing the corresponding immunoglobulin to which the antibody portion has specificity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.